>>Signaling Pathways>> Chromatin/Epigenetics>> Aurora Kinase>>Hesperadin hydrochloride

Hesperadin hydrochloride

Catalog No.GC50050

헤스페라딘 염산염은 오로라 A 및 B의 ATP 경쟁 인돌리논 억제제입니다. 헤스페라딘 염산염은 250nM의 IC50으로 오로라 B를 억제합니다.

Products are for research use only. Not for human use. We do not sell to patients.

Hesperadin hydrochloride Chemical Structure

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$64.00
재고 있음
5mg
US$56.00
재고 있음
10mg
US$105.00
재고 있음
50mg
US$378.00
재고 있음
100mg
US$644.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ATP-competitive inhibitor of Aurora B kinase (IC50 = 250 nM). Prevents chromosome alignment and segregation; also induces polyploidy and prevents histone H3-Ser10 phosphorylation. Overrides the spindle assembly checkpoint and induces mitotic exit in monastrol- and taxol-treated HeLa cells.

Hauf et al (2003) The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint. J.Cell.Biol. 161 281 PMID:12707311 |Jetton et al (2009) The cell cycle as a therapeutic target against Trypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms. Mol.Microbiol. 72 442 PMID:19320832 |Sessa et al (2005) Mechanism of Aurora B activation by INCENP and inhibition by Hesperadin. Mol.Cell. 18 379 PMID:15866179

리뷰

Review for Hesperadin hydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Hesperadin hydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.